SRX Health Solutions Inc SEC Filings

JPMorgan Chase Financial Company LLC is offering Uncapped Buffered Return Enhanced Notes (the “notes”) fully and unconditionally guaranteed by JPMorgan Chase & Co. The preliminary pricing supplement (Rule 424(b)(2)) describes a five-year structured product linked separately to the Nasdaq-100 Index® (NDX), Russell 2000® Index (RTY) and S&P 500® Index (SPX). Payments are based on the performance of the least-performing index, not on an equal-weighted basket.

Key economic terms

• Upside participation: at least 1.336× any positive return of the least-performing index; the exact factor will be set on the pricing date (on or about 18 Jul 2025).
• Downside buffer: investors are protected against the first 20% decline of each index. Losses beyond the buffer are linear, exposing principal to a maximum 80% loss.
• Maturity: 23 Jul 2030; observation date 18 Jul 2030.
• Denomination: $1,000 minimum and integral multiples.
• Fees: selling commissions up to $41.25 per $1,000.
• Estimated value: approximately $940.40 today; final estimate disclosed at pricing but not below $900.
• CUSIP: 48136FVS8. The notes will not be listed on any exchange.

Payout mechanics

• If the final level of each index exceeds its initial level, payment = $1,000 + (Least-Performing Index Return × Upside Factor × $1,000). Because the product is uncapped, gains are unlimited.
• If any index finishes ≤ its initial level but not lower by more than 20%, investors receive par.
• If any index falls by >20%, payment = $1,000 + [$1,000 × (Least-Performing Index Return + 20%)], resulting in up to 80% principal loss.

Illustrative examples (Upside Factor 1.336, buffer 20%): a 10% gain in the least-performing index yields a 13.36% total return ($1,133.60); a 40% decline produces a 20% loss ($800); a 60% decline produces a 40% loss ($600).

Risk disclosures highlight (i) credit exposure to both JPMorgan entities, (ii) lack of periodic interest or dividends, (iii) potential conflicts arising from JPMorgan’s hedging and secondary-market activities, (iv) liquidity risk because the notes are unlisted and any resale depends on J.P. Morgan Securities LLC’s bid, (v) estimated value below issue price, and (vi) U.S. tax treatment subject to confirmation; Section 871(m) is expected not to apply.

Indices overview (historic closes on 14 Jul 2025): NDX 22,855.63; RTY 2,249.729; SPX 6,268.56. Past performance is not indicative of future results.

LuxUrban Hotels Inc. (Nasdaq: LUXHP) has filed Form 25 with Nasdaq, initiating the removal of its Common Stock and 13.00% Series A Cumulative Redeemable Preferred Stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

The filing was signed by Nasdaq on 11 July 2025, indicating that the exchange believes it has met all regulatory requirements to delist the securities. The notice references Rule 12d2-2(b), which covers exchange-initiated delistings, suggesting the action was driven by Nasdaq rather than a voluntary request from the issuer. Once the Form 25 becomes effective (typically ten days after filing), the securities will no longer be traded on Nasdaq and their registration under the Exchange Act will be withdrawn 90 days thereafter, unless the company takes alternative steps.

Key implications for investors:

• Loss of Nasdaq listing often results in reduced liquidity, wider bid-ask spreads, and potential migration to over-the-counter markets.
• Delisting may trigger covenants in debt or preferred instruments and can affect institutional ownership thresholds tied to exchange-listed status.
• No financial performance data or explanation for the delisting is provided in this filing; investors must look for additional disclosures or 8-K filings for context.